TGFB1 and pulmonary fibrosis: An inhibitor of TGF-β and downstream signaling mechanisms, pirfenidone, was FDA approved in 2014 for the treatment of idiopathic pulmonary fibrosis, indicating the therapeutic potential of inhibiting TGF-β signaling in a clinical setting [304,305].